8-K
filed December 10, 2025, 6:59 PM ET
ticker CYCU
CIK 0001868419
other material
confidence medium
sentiment positive
materiality 0.50
Cycurion CEO highlights 2025 achievements: IPO, debt reduction, acquisitions; eyes 2026 growth
Cycurion, Inc.
- Went public February 2025; focused on right-sizing and strengthening balance sheet.
- Paid down significant debt and used ELOC to support acquisitions and talent.
- 2026 outlook: organic growth, corporate expansion, new products and services.
- CEO cites 'seamless alignment' with clients and continued growth in state and federal sectors.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001868419-25-000033
- form_type
- 8-K
- ticker
- CYCU
- cik
- 0001868419
- company_name
- Cycurion, Inc.
- filed_at
- 2025-12-10T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:40.918531+00:00
- generated_at
- 2026-05-16T13:40:25.871439+00:00
- sec_items
- ["8.01", "9.01"]
- event_type
- other_material
- sentiment
- positive
- materiality_score
- 0.5
- calibrated_materiality_score
- 0.5
- confidence
- medium
- secwatch_canonical_url
- https://secwatch.observer/filing/0001868419-25-000033
- json_url
- https://secwatch.observer/filing/0001868419-25-000033.json
- markdown_url
- https://secwatch.observer/filing/0001868419-25-000033.md
- text_url
- https://secwatch.observer/filing/0001868419-25-000033.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1868419/000186841925000033/0001868419-25-000033-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1868419/000186841925000033/cycu-20251209.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
NRXP
NRx Pharmaceuticals proposes public offering of common stock; terms not set
NRX Pharmaceuticals, Inc.
June 2, 2026, 5:30 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
AVA
Avista signs non-binding MOU for 125 MW load, expandable to 500 MW by 2032
AVISTA CORP
June 2, 2026, 5:02 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
ARVN
Arvinas to out-license ARV-806 after completing Phase 1 dose escalation
ARVINAS, INC.
June 2, 2026, 4:39 PM ET
other_material
Items 7.01, 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
JAGX
Jaguar Health issues 64,668 common shares for Series Q Preferred; annual meeting adjourned to June 8
Jaguar Health, Inc.
June 2, 2026, 4:10 PM ET
other_material
Items 1.01, 3.02, 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
OTAI
Starlink AI Acquisition closes partial over-allotment, adds $5M to trust
Starlink AI Acquisition Corp
June 2, 2026, 4:05 PM ET
other_material
Items 3.02, 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
MLI
Mueller Industries announces 2-for-1 stock split; record date June 25, 2026
MUELLER INDUSTRIES INC
June 2, 2026, 10:47 AM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
SLS
SELLAS Life Sciences raised $28.7M from warrant exercises in Apr-May 2026
SELLAS Life Sciences Group, Inc.
June 2, 2026, 8:30 AM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
MBOT
Microbot Medical secures first North Carolina customer for LIBERTY robotic system
Microbot Medical Inc.
June 2, 2026, 8:30 AM ET
other_material
Items 7.01, 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.